1. Home
  2. CUE vs LICN Comparison

CUE vs LICN Comparison

Compare CUE & LICN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CUE
  • LICN
  • Stock Information
  • Founded
  • CUE 2014
  • LICN 2004
  • Country
  • CUE United States
  • LICN China
  • Employees
  • CUE N/A
  • LICN N/A
  • Industry
  • CUE Biotechnology: Pharmaceutical Preparations
  • LICN
  • Sector
  • CUE Health Care
  • LICN
  • Exchange
  • CUE Nasdaq
  • LICN Nasdaq
  • Market Cap
  • CUE 94.4M
  • LICN 8.7M
  • IPO Year
  • CUE 2018
  • LICN 2023
  • Fundamental
  • Price
  • CUE $1.43
  • LICN $0.07
  • Analyst Decision
  • CUE Strong Buy
  • LICN
  • Analyst Count
  • CUE 5
  • LICN 0
  • Target Price
  • CUE $5.00
  • LICN N/A
  • AVG Volume (30 Days)
  • CUE 234.5K
  • LICN 22.4M
  • Earning Date
  • CUE 03-10-2025
  • LICN 12-31-2024
  • Dividend Yield
  • CUE N/A
  • LICN N/A
  • EPS Growth
  • CUE N/A
  • LICN 36.90
  • EPS
  • CUE N/A
  • LICN 0.28
  • Revenue
  • CUE $9,532,000.00
  • LICN $41,929,000.00
  • Revenue This Year
  • CUE $73.11
  • LICN N/A
  • Revenue Next Year
  • CUE $11.02
  • LICN N/A
  • P/E Ratio
  • CUE N/A
  • LICN $0.24
  • Revenue Growth
  • CUE 149.53
  • LICN 24.86
  • 52 Week Low
  • CUE $0.45
  • LICN $0.06
  • 52 Week High
  • CUE $2.37
  • LICN $2.44
  • Technical
  • Relative Strength Index (RSI)
  • CUE 54.52
  • LICN 25.94
  • Support Level
  • CUE $1.22
  • LICN $0.06
  • Resistance Level
  • CUE $1.54
  • LICN $0.10
  • Average True Range (ATR)
  • CUE 0.12
  • LICN 0.01
  • MACD
  • CUE 0.00
  • LICN 0.02
  • Stochastic Oscillator
  • CUE 67.65
  • LICN 33.33

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

About LICN Lichen China Limited

Lichen China Ltd is a holding company. The company, along with its subsidiaries provides financial and taxation solution services; education support services; and software and maintenance services. The company generates Majority revenue from Financial and taxation solution services.

Share on Social Networks: